BACKGROUND: Invasive mold infections (IMIs) are common in individuals who have undergone hematopoietic stem cell transplantation (HSCT). We sought to determine clinical and biological risk factors for different IMIs during each period (early and late) after allogeneic HSCT. METHODS: Cases of proven and probable IMI diagnosed in HSCT recipients at the Fred Hutchinson Cancer Research Center (Seattle, WA) from 1 January 1998 through 31 December 2002 were included. Survival was estimated with Kaplan-Meier curves, and Cox regression models were used for multivariable analyses. RESULTS: During the study period, 1248 patients underwent allogeneic HSCT; 163 (13.1%) received a diagnosis of probable or proven IMI. The majority of cases were caused by Aspergillus species (88%). The incidence of IMI caused by other molds remained low (<2%) over the 4-year study period. Risk factors for IMI early after HSCT and late after HSCT differed, with host variables (age) and transplant variables (human leukocyte antigen match) predominating as early risk factors and other clinical complications (graft-versus-host disease and cytomegalovirus disease) predominating later. Biological risk factors that were important during all periods included multiple cytopenias (neutropenia, lymphopenia, and monocytopenia) and iron overload. CONCLUSIONS: Risk factors for invasive aspergillosis after allogeneic HSCT are multifactorial and differ according to timing after HSCT. Increased attention should be placed on understanding the immunopathogenesis of fungal disease after HSCT.
BACKGROUND:Invasive mold infections (IMIs) are common in individuals who have undergone hematopoietic stem cell transplantation (HSCT). We sought to determine clinical and biological risk factors for different IMIs during each period (early and late) after allogeneic HSCT. METHODS: Cases of proven and probable IMI diagnosed in HSCT recipients at the Fred Hutchinson Cancer Research Center (Seattle, WA) from 1 January 1998 through 31 December 2002 were included. Survival was estimated with Kaplan-Meier curves, and Cox regression models were used for multivariable analyses. RESULTS: During the study period, 1248 patients underwent allogeneic HSCT; 163 (13.1%) received a diagnosis of probable or proven IMI. The majority of cases were caused by Aspergillus species (88%). The incidence of IMI caused by other molds remained low (<2%) over the 4-year study period. Risk factors for IMI early after HSCT and late after HSCT differed, with host variables (age) and transplant variables (human leukocyte antigen match) predominating as early risk factors and other clinical complications (graft-versus-host disease and cytomegalovirus disease) predominating later. Biological risk factors that were important during all periods included multiple cytopenias (neutropenia, lymphopenia, and monocytopenia) and iron overload. CONCLUSIONS: Risk factors for invasive aspergillosis after allogeneic HSCT are multifactorial and differ according to timing after HSCT. Increased attention should be placed on understanding the immunopathogenesis of fungal disease after HSCT.
Authors: W B Grow; J S Moreb; D Roque; K Manion; H Leather; V Reddy; S A Khan; K J Finiewicz; H Nguyen; C J Clancy; P S Mehta; J R Wingard Journal: Bone Marrow Transplant Date: 2002-01 Impact factor: 5.483
Authors: Marion Kauth; Evelin Grage-Griebenow; Gernot Rohde; Olaf Anhenn; Almut Wiethege; Gerhard Schultze-Werninghaus; Albrecht Bufe Journal: Int Arch Allergy Immunol Date: 2006-10-18 Impact factor: 2.749
Authors: S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh Journal: Clin Infect Dis Date: 2001-11-26 Impact factor: 9.079
Authors: W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum Journal: N Engl J Med Date: 2001-01-18 Impact factor: 91.245
Authors: Aimee K Zaas; Guochun Liao; Jason W Chien; Clarice Weinberg; David Shore; Steven S Giles; Kieren A Marr; Jonathan Usuka; Lauranell H Burch; Lalith Perera; John R Perfect; Gary Peltz; David A Schwartz Journal: PLoS Genet Date: 2008-06-20 Impact factor: 5.917
Authors: Paul J Martin; Terry Furlong; Scott D Rowley; Steven A Pergam; Michele Lloid; Mark M Schubert; Kevin J Horgan; Barry E Storer Journal: Biol Blood Marrow Transplant Date: 2011-11-09 Impact factor: 5.742
Authors: P Montesinos; R Rodríguez-Veiga; B Boluda; D Martínez-Cuadrón; I Cano; A Lancharro; J Sanz; M J Arilla; F López-Chuliá; I Navarro; I Lorenzo; M Salavert; J Pemán; P Calvillo; J Martínez; N Carpio; I Jarque; G F Sanz; M A Sanz Journal: Bone Marrow Transplant Date: 2015-08-17 Impact factor: 5.483
Authors: D Neofytos; S Treadway; D Ostrander; C D Alonso; K L Dierberg; V Nussenblatt; C M Durand; C B Thompson; K A Marr Journal: Transpl Infect Dis Date: 2013-02-21 Impact factor: 2.228
Authors: Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Jennifer M Puck; Rebecca H Buckley; Fabio Candotti; Mary Ellen Conley; Thomas A Fleisher; H Bobby Gaspar; Donald B Kohn; Hans D Ochs; Richard J O'Reilly; J Douglas Rizzo; Chaim M Roifman; Trudy N Small; William T Shearer Journal: J Allergy Clin Immunol Date: 2009-12 Impact factor: 10.793
Authors: U Gergis; K Markey; J Greene; M Kharfan-Dabaja; T Field; G Wetzstein; M J Schell; Y Huang; C Anasetti; J Perkins Journal: Bone Marrow Transplant Date: 2009-08-17 Impact factor: 5.483